• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Res Hepatol Gastroenterol . Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: a multic

tetano

tetano

Editor, Senior Moderator
Clin Res Hepatol Gastroenterol


. 2023 Jun 1;102150.
doi: 10.1016/j.clinre.2023.102150. Online ahead of print. Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: a multicenter study

Yinuo Yang[SUP] 1 [/SUP], Xuemei Li[SUP] 2 [/SUP], Xinya Zhao[SUP] 3 [/SUP], Yiqing Liu[SUP] 4 [/SUP], Tong Zhao[SUP] 5 [/SUP], Qiang Zhu[SUP] 6 [/SUP]



Affiliations
Abstract

Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease.

Keywords: Antibody response; Chronic liver disease; SARS-CoV-2; Vaccine.




​
 
You must log in or register to reply here.
Back
Top Bottom